Advertisement

Panel recommends labeling change for AstraZeneca's diabetes drug Onglyza

By Steven Ross Johnson  |  April 14, 2015

An advisory panel to the U.S. Food and Drug Administration voted Tuesday to recommend the agency require drugmaker AstraZeneca to change the labeling of its diabetes medication Onglyza to add safety information to reflect a heightened risk for heart failure associated with its use.

China fines GlaxoSmithKline $492M for bribery

By Associated Press  |  September 19, 2014

Drugmaker GlaxoSmithKline was fined $492 million on Friday for bribing doctors in China, the biggest such penalty ever imposed by a Chinese court.

Pfizer's 2Q profit sinks 79% but tops forecasts

By Associated Press  |  July 29, 2014

Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

Merck 2Q profit more than doubles

By Associated Press  |  July 29, 2014

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, improve its profit forecast and top analysts' expectations.

Antiviral-drug maker fights pediatricians' new advice

By Associated Press  |  July 28, 2014

A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

Tax reform fears driving Big Pharma mergers

Tax reform fears driving Big Pharma mergers

By Beth Kutscher  |  July 19, 2014

The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.

Pfizer withdraws spurned offer for AstraZeneca

Pfizer withdraws spurned offer for AstraZeneca

By Associated Press  |  May 26, 2014

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.

Drug prices spotlighted in AstraZeneca deal

By Beth Kutscher  |  May 24, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.

AstraZeneca holding firm against Pfizer's advances

AstraZeneca holding firm against Pfizer's advances

By Beth Kutscher  |  May 23, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...

Pfizer faces lawsuits that claim Lipitor caused diabetes

Pfizer faces lawsuits that claim Lipitor caused diabetes

By Joe Carlson  |  May 17, 2014

Several hundred women are suing Pfizer in federal court, alleging the company knew that women taking Lipitor faced an increased risk of developing Type 2 diabetes and that Pfizer's warning label did not clearly describe that risk.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.